Verastem | VSTM - Sales Revenues


Verastem reported $0 in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
AstraZeneca USD 15.5B 313M Dec/2025
Curis USD 2.55M 460K Jun/2024
Cytokinetics USD 17.76M 15.83M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Laboratory Of America USD 3.52B 40M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Verastem USD 0 10M Sep/2024